Moderate hemophilia ANews & Research
3 curated articles for Moderate hemophilia A — FDA updates, peer-reviewed research, clinical-trial milestones, and sponsor press releases. Sorted newest-first.
- Cell biology international May 14, 2026
The p. Arg 1800 His Mutation of Factor VIII Results in Moderate Hemophilia A Due to Defective Processing and Stability of Functional Protein.
Haemophilia A (HA) is a rare congenital, recessive X-linked bleeding disorders caused by the lack or deficiency of clotting factor VIII (FVIII). Missense variants, which can alter protein structure, conformation and immunogenicity, are found in nearly all individuals with mild or moderate hemophilia...
Why it matters: Recent peer-reviewed research on Moderate hemophilia A that may be relevant for patients and caregivers.
- Frontiers in pediatrics Apr 2, 2026
Delayed diagnosis of hemophilia A presenting as chronic joint swelling: a case report.
Chronic joint swelling in children usually requires differential diagnosis for juvenile idiopathic arthritis (JIA). Hemophilic arthropathy, despite its rarity, may be an important differential entity, and its identification is challenging in the absence of significant bleeding history. A 2-year-old ...
Why it matters: Recent peer-reviewed research on Moderate hemophilia A that may be relevant for patients and caregivers.
- BreakingFDA Oct 25, 2025
Hemlibra Expanded Indication Approved for All Hemophilia A
FDA approved expanded indication for Hemlibra covering all severity levels regardless of inhibitor status.
Why it matters: Broadens access to the most widely used hemophilia A prophylaxis.
More on Moderate hemophilia A
Articles aggregated from peer-reviewed journals (PubMed), sponsor press releases, SEC 8-K filings, and FDA announcements. Original-source links are preserved on each article page. Editorial tags (Breaking / Notable / Update) reflect UniteRare's curation-time priority assessment.